Unknown NA INTERVENTIONAL 2-arm NCT00935246

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Sponsor: H. Lundbeck A/S

Conditions Adverse Reaction to Drug Continuous Antidepressant Abuse Depression

Updated 7 times since 2017 Last updated: Dec 30, 2015 Started: Dec 31, 2008 Primary completion: Oct 31, 2011 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00935246, this NA trial focuses on Adverse Reaction to Drug and Continuous Antidepressant Abuse and remains ongoing. Sponsored by H. Lundbeck A/S, it has been updated 7 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown NA
Sep 2024 — Sep 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Unknown Status NA

Status: Active Not Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Active Not Recruiting NA

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S
Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kangnam, South Korea